Can Regeneron’s Odronextamab Stand Out With Better Safety?

Entering Crowded CD20 Bispecific Field

 
• By Alaric DeArment
The Regeneron, Genentech and AbbVie booths at the 2023 ASH conference • Source: Scrip

More from Immuno-oncology

More from Anticancer